Associated Genetic Biomarkers
NCI Definition: A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei. Patients with limited disease generally have an excellent prognosis. In the more advanced stages, the prognosis is poor. (WHO, 2001) 
There are 29 clinical trials for mycosis fungoides, of which 24 are open and 5 are completed or closed. Of the trials that contain mycosis fungoides as an inclusion criterion, 12 are phase 1 (9 open), 4 are phase 1/phase 2 (4 open), 12 are phase 2 (11 open), and 1 is phase 3 (0 open).
TNFRSF8, Tumor, and CD5 are the most frequent gene inclusion criteria for mycosis fungoides clinical trials .
Pembrolizumab, brentuximab vedotin, and cyclophosphamide are the most common interventions in mycosis fungoides clinical trials.
Significant Genes in Mycosis Fungoides
ALK is an inclusion eligibility criterion in 1 clinical trial for mycosis fungoides, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mycosis fungoides as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.